You are here: Industry Insights > cancer

News List

CDC Provides Clarification of Opioid Prescribing Guideline drugs
April 25, 2019
CDC Provides Clarification of Opioid Prescribing Guideline
Cancer Research UK, Ono and LifeArc to identify new cancer drugs pharmaceutical-technology
April 24, 2019
Cancer Research UK (CRUK) has partnered with Japanese drugmaker Ono Pharmaceutical and not-for-profit LifeArc to identify new immunotherapy drug targets for cancer.
Personalizing precision medicine with combination therapies improves outcomes in cancer worldpharmanews
April 24, 2019
Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor.
Merck’s Keytruda gets FDA approval to treat kidney cancer pharmaceutical-technology
April 24, 2019
Merck has received US Food and Drug Administration (FDA) approval for its anti-PD-1 therapy Keytruda to treat advanced renal cell carcinoma (RCC) patients.
MDxHealth's SelectMDx Test Successfully Stratifies Men Who May Benefit from mp-MRI for Prostate Cancer Diagnosis b3cnewswire
April 23, 2019
MDxHealth's SelectMDx Test Successfully Stratifies Men Who May Benefit from mp-MRI for Prostate Cancer Diagnosis.
Puma licences breast cancer therapy to Pierre Fabre in Europe pharmaceutical-technology
April 23, 2019
Puma licences breast cancer therapy to Pierre Fabre in Europe.
AstraZeneca’s Lynparza gets EC approval for breast cancer pharmaceutical-technology
April 23, 2019
The European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer in adults.
Repurposing cancer drugs may lead to a new approach to treating TB europeanpharmaceuticalreview
April 22, 2019
Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease: tuberculosis (TB)…
Moleculin Announces Significant Discovery in Lung Cancer Models americanpharmaceuticalreview
April 22, 2019
Moleculin Announces Significant Discovery in Lung Cancer Models...
Janssen’s bladder cancer drug Balversa receives FDA nod pharmaceutical-technology
April 22, 2019
Janssen Pharmaceutical has received the US Food and Drug Administration (FDA) approval for the drug Balversa (erdafitinib) to treat adults with locally advanced or metastatic urothelial carcinoma (mUC).